Venous Disease Classification (CEAP): C2 or C3 Clinical Trial
Official title:
EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS
Chronic Venous Disorder is the most prevalent vascular disease. It is multifactorial
pathology that has an important impact on quality of life and represents a significant
public health concern, due to its very high frequency in all European and American (north
and south) countries.
Venous pathology develops when venous pressure is increased and return of blood is impaired
through several mechanisms. Wish induce leg symptoms (tingling, aching, burning, pain,
muscle cramps, sensation of swelling, sensations of throbbing or heaviness, itching skin,
restless legs, leg tiredness and/or fatigue.
The aims of this research is to study the effects on microcirculatory activity (activity on
very small vessels) of CYCLO 3 ® FORT, MPFF (Micronised Purified Flavonoid Fraction) and
Placebo after 8 week of treatment by Microscan, and Duplex, two imaging non-invasive
technologies will be performed to obtain measurements of microcirculatory parameters in
standardized and reproducible conditions for all the participants. In addition, will assess,
in blood samples, the inflammatory biomarkers .
n/a